About: COVID-19 and Cancer: a Comprehensive Review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 and Cancer: a Comprehensive Review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 and Cancer: a Comprehensive Review
Creator	Abdou, Yara Ernstoff, Marc Gosain, Rohit Puzanov, Igor Rana, Navpreet Singh, Abhay
Source	Medline; PMC
abstract	PURPOSE OF REVIEW: The outbreak of the novel coronavirus disease 2019 (COVID-19) has emerged to be the biggest global health threat worldwide, which has now infected over 1.7 million people and claimed more than 100,000 lives around the world. Under these unprecedented circumstances, there are no well-established guidelines for cancer patients. RECENT FINDINGS: The risk for serious disease and death in COVID-19 cases increases with advancing age and presence of comorbid health conditions. Since the emergence of the first case in Wuhan, China, in December 2019, tremendous research efforts have been underway to understand the mechanisms of infectivity and transmissibility of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a fatal virus responsible for abysmal survival outcomes. To minimize the mortality rate, it becomes prudent to identify symptoms promptly and employ treatments appropriately. Even though no cure has been established, multiple clinical trials are underway to determine the most optimal strategy. Managing cancer patients under these circumstances is rather challenging, given their vulnerable status and the aggressive nature of their underlying disease. SUMMARY: In this comprehensive review, we discuss the impact of COVID-19 on health and the immune system of those affected, reviewing the latest treatment approaches and ongoing clinical trials. Additionally, we discuss challenges faced while treating cancer patients and propose potential approaches to manage this vulnerable population during this pandemic.
has issue date	2020-05-08(xsd:dateTime)
bibo:doi	10.1007/s11912-020-00934-7
bibo:pmid	32385672
has license	no-cc
sha1sum (hex)	0f02dd0896c275e816e96ab61774c65c9ca45ff6
schema:url	https://doi.org/10.1007/s11912-020-00934-7
resource representing a document's title	COVID-19 and Cancer: a Comprehensive Review
has PubMed Central identifier	PMC7206576
has PubMed identifier	32385672
schema:publication	Curr Oncol Rep
resource representing a document's body	covid:0f02dd0896c275e816e96ab61774c65c9ca45ff6#body_text
is schema:about of	named entity 'prudent' named entity 'outbreak' named entity 'severe acute respiratory syndrome coronavirus' named entity 'mechanisms' named entity 'comorbid' named entity 'COVID-19' named entity 'MANAGING' named entity 'COMORBID' named entity 'STRATEGY' named entity 'global health' named entity 'fatal' named entity 'patients' named entity 'health' named entity 'strategy' named entity 'health' named entity 'cases' named entity 'survival' named entity 'SARS-CoV-2' named entity 'coronavirus disease 2019' named entity 'global health' named entity 'infectivity' named entity 'transmissibility' named entity 'COVID-19' named entity 'intestine' named entity 'Acalabrutinib' named entity 'serum' named entity 'Wuhu' named entity 'ARDS' named entity 'etiology' named entity 'inflammatory response' named entity 'sHLH' named entity 'tumors' named entity 'tyrosine kinase inhibitor' named entity 'epidemic diseases' named entity 'convalescent plasma' named entity 'randomized controlled trial' named entity 'fatigue' named entity 'outpatient settings' named entity 'SARS-CoV-1' named entity 'anti-inflammatory' named entity 'stay at home' named entity 'SARS-CoV' named entity 'tocilizumab' named entity 'fibrinolytic therapy' named entity 'meta-analysis' named entity 'DIC' named entity 'glycoprotein' named entity 'elective surgeries' named entity 'compassionate-use' named entity 'breast cancer' named entity 'China' named entity 'Europe' named entity 'methylprednisolone' named entity 'vaccine' named entity '5-fluorouracil' named entity 'ACE2' named entity 'RCT' named entity 'China' named entity 'HSCT' named entity 'lymphocyte' named entity 'American College of Surgeons' named entity 'cytokine' named entity 'SARS-CoV-2' named entity 'immunocompromised' named entity 'palliative' named entity 'antiviral agents' named entity 'hematological malignancies' named entity 'corticosteroids' named entity 'decoction' named entity 'binding site' named entity 'respiratory distress' named entity 'IL-1' named entity 'lymphocytes' named entity 'COVID' named entity 'COVID' named entity 'interleukin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software